BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 16566422)

  • 1. [Complete atrioventricular block during galantamine therapy].
    Leentjens AF; Kragten JA
    Ned Tijdschr Geneeskd; 2006 Mar; 150(10):563-6. PubMed ID: 16566422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Complete atrioventricular block during galantamine therapy].
    Schölzel-Dorenbos CJ
    Ned Tijdschr Geneeskd; 2006 Apr; 150(17):989-90; author reply 990. PubMed ID: 17225744
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of the effects of galantamine on cardiac function in elderly patients with Alzheimer's disease.
    Isik AT; Bozoglu E; Naharci MI; Kilic S
    Am J Geriatr Pharmacother; 2010 Oct; 8(5):454-9. PubMed ID: 21335298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
    Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
    Chu LW; Yik PY; Mok W; Chung CP
    Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Galantamine: a novel cholinergic agent for Alzheimer's disease].
    Olazarán J; García G
    Neurologia; 2002 Oct; 17(8):429-36. PubMed ID: 12396973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
    Prescrire Int; 2007 Oct; 16(91):197-8. PubMed ID: 17926835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacotherapy of a patient with Alzheimer's disease: interactions with the antidementive galantamine].
    Schwalbe O; Wunderlich S; Kloft C
    Med Monatsschr Pharm; 2006 Jun; 29(6):222-4. PubMed ID: 16792199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients.
    Senanarong V; Poungvarin N; Phanthumchinda K; Thavichachart N; Chankrachang S; Praditsuwan R; Nidhinandana S
    J Med Assoc Thai; 2009 Mar; 92 Suppl 2():S12-8. PubMed ID: 19562980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological therapy in Alzheimer's disease. Current clinical practice in The Netherlands].
    Schölzel-Dorenbos CJ;
    Tijdschr Gerontol Geriatr; 2005 Jul; 36(3):122-6. PubMed ID: 16078659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Observational study on safety, tolerability and effectiveness of galantamine in patients with mild to moderately severe Alzheimer's disease].
    Blesa R; García Ribas G; Galdós L; Olascoaga J; Amer G; Marey López J; Barquero M; Marsall C; Ezpeleta D
    Neurologia; 2006; 21(6):289-96. PubMed ID: 16799903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bradycardia induced by galantamine].
    Leclerc C; Genuit-Leclerc L; Citerne O
    Ann Fr Anesth Reanim; 2008 Nov; 27(11):949-52. PubMed ID: 19008069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversible Pisa syndrome (pleurothotonus) due to the cholinesterase inhibitor galantamine: case report.
    Cossu G; Melis M; Melis G; Maccioni E; Putzu V; Catte O; Putzu PF
    Mov Disord; 2004 Oct; 19(10):1243-4. PubMed ID: 15389998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of rivastigmine or galantamine and risk of adverse cardiac events: a database study from the Netherlands.
    Kröger E; Berkers M; Carmichael PH; Souverein P; van Marum R; Egberts T
    Am J Geriatr Pharmacother; 2012 Dec; 10(6):373-80. PubMed ID: 23217530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.
    López-Pousa S; Olmo JG; Franch JV; Estrada AT; Cors OS; Nierga IP; Gelada-Batlle E
    Age Ageing; 2006 Jul; 35(4):365-71. PubMed ID: 16788079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
    Rockwood K; Dai D; Mitnitski A
    Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of Galantamine on sleep quality in Thai Alzheimer's disease patients.
    Chankrachang S; Senanarong V; Poungvarin N; Phanthumchinda K; Tavichachart N; Praditsuwan R; Nidhinandana S
    J Med Assoc Thai; 2008 Sep; 91(9):1343-9. PubMed ID: 18843862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galantamine in Alzheimer's disease.
    Razay G; Wilcock GK
    Expert Rev Neurother; 2008 Jan; 8(1):9-17. PubMed ID: 18088197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galantamine: use in Alzheimer's disease and related disorders.
    Bullock R
    Expert Rev Neurother; 2004 Mar; 4(2):153-63. PubMed ID: 15853556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.